PRIMAXIN IV- imipenem and cilastatin sodium injection, powder, for solution

PRIMAXIN by

Drug Labeling and Warnings

PRIMAXIN by is a Prescription medication manufactured, distributed, or labeled by Merck Sharp & Dohme LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Lower Respiratory Tract Infections

    PRIMAXIN for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella species, Serratia marcescens.

    1.2 Urinary Tract Infections (complicated and uncomplicated)

    PRIMAXIN is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa.

    1.3 Intra-Abdominal Infections

    PRIMAXIN is indicated for the treatment of intra-abdominal infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis, Fusobacterium species.

    1.4 Gynecologic Infections

    PRIMAXIN is indicated for the treatment of gynecologic infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species, Escherichia coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis.

    1.5 Bacterial Septicemia

    PRIMAXIN is indicated for the treatment of bacterial septicemia caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species including B. fragilis.

    1.6 Bone and Joint Infections

    PRIMAXIN is indicated for the treatment of bone and joint infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa.

    1.7 Skin and Skin Structure Infections

    PRIMAXIN is indicated for the treatment of skin and skin structure infections caused by susceptible strains of Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing isolates), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species.

    1.8 Endocarditis

    PRIMAXIN is indicated for the treatment of endocarditis caused by susceptible strains of Staphylococcus aureus (penicillinase-producing isolates).

    1.9 Limitations of Use

    1.10 Usage

    To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN and other antibacterial drugs, PRIMAXIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosage in Adults

    For Intravenous Injection Only

    • The dosage of PRIMAXIN in adult patients should be based on suspected or confirmed pathogen susceptibility as shown in Table 1 below. The dosage recommendations for PRIMAXIN represent the quantity of imipenem to be administered. An equivalent amount of cilastatin is also present in the solution.
    • These doses should be used for patients with creatinine clearance of greater than or equal to 90 mL/min. A reduction in dose must be made for patients with creatinine clearance less than 90 mL/min as shown in Table 3 [see Dosage and Administration (2.3)].
    • Recommend that the maximum total daily dosage not exceed 4 g/day.
    • Administer 500 mg by intravenous infusion over 20 to 30 minutes.
    • Administer 1000 mg by intravenous infusion over 40 to 60 minutes.
    • In patients who develop nausea during the infusion, the rate of infusion may be slowed.
    Table 1: Dosage of PRIMAXIN in Adult Patients with Creatinine Clearance Greater than or Equal to 90 mL/min
    Suspected or Proven Pathogen SusceptibilityDosage of PRIMAXIN
    If the infection is suspected or proven to be due to a susceptible bacterial species500 mg every 6 hours
    OR
    1000 mg every 8 hours
    If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology (12.4)]1000 mg every 6 hours

    2.2 Dosage in Pediatric Patients

    PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures [see Use in Specific Populations (8.4)].

    PRIMAXIN is not recommended in pediatric patients <30 kg with renal impairment, as no data are available [see Use in Specific Populations (8.4)].

    Based on studies in adults, the maximum total daily dose in pediatric patients should not exceed 4 g/day [see Dosage and Administration (2.1)].

    The recommended dosage for pediatric patients with non-CNS infections is shown in Table 2 below:

    Table 2: Recommended PRIMAXIN Dosage in Pediatric Patients for Non-CNS Infections
    AgeDose (mg/kg) *,†Frequency (hours)
  • * Doses less than or equal to 500 mg should be given by intravenous infusion over 20 to 30 minutes
  • † Doses greater than 500 mg should be given by intravenous infusion over 40 to 60 minutes Recommend that the maximum total daily dosage not exceed 4g/day
    		•
    Greater than or equal to 3 Months of Age
     15-25 mg/kgEvery 6 hours
    Less than or equal to 3 months of age (Greater than or equal to 1,500 g body weight)
    4 weeks to 3 months of age25 mg/kgEvery 6 hours
    1 to 4 weeks of age25 mg/kgEvery 8 hours
    Less than 1 week of age25 mg/kgEvery 12 hours

    2.3 Dosage in Adult Patients with Renal Impairment

    Patients with creatinine clearance less than 90 mL/min require dosage reduction of PRIMAXIN as indicated in Table 3. The serum creatinine should represent a steady state of renal function. Use the Cockcroft-Gault method described below to calculate the creatinine clearance:

    Males:(weight in kg) × (140-age in years)
     (72) × serum creatinine (mg/100 mL)
    Females:(0.85) × (value calculated for males)
    Table 3: Dosage of PRIMAXIN for Adult Patients in Various Renal Function Groups Based on Estimated Creatinine Clearance (CLcr)
     Creatinine clearance (mL/min)
     Greater than or equal to 90Less than 90 to greater than or equal to 60Less than 60 to greater than or equal to 30Less than 30 to greater than or equal to 15
  • * Administer doses less than or equal to 500 mg by intravenous infusion over 20 to 30 minutes. Discard unused portion of the infusion solution.
  • † Administer doses greater than 500 mg by intravenous infusion over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed.
    		•
    Dosage of PRIMAXIN*,†
    If the infection is suspected or proven to be due to a susceptible bacterial species:    		500 mg every 6 hours400 mg every 6 hours300 mg every 6 hours200 mg every 6 hours
    OR
    1000 mg every 8 hours500 mg every 6 hours500 mg every 8 hours500 mg every 12 hours
    Dosage of PRIMAXIN*,†
    If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology (12.4)]:    		1000 mg every 6 hours750 mg every 8 hours500 mg every 6 hours500 mg every 12 hours

    In patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min, there may be an increased risk of seizures [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)]. Patients with creatinine clearance less than 15 mL/min should not receive PRIMAXIN unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of PRIMAXIN for patients undergoing peritoneal dialysis.

    2.4 Dosage in Hemodialysis Patients

    When treating patients with creatinine clearances of less than 15 mL/min who are undergoing hemodialysis, use the dosage recommendations for patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min in Table 3 above [see Dosage and Administration (2.3)]. Both imipenem and cilastatin are cleared from the circulation during hemodialysis. The patient should receive PRIMAXIN after hemodialysis and at intervals timed from the end of that hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, PRIMAXIN is recommended only when the benefit outweighs the potential risk of seizures [see Warnings and Precautions (5.2)].

    2.5 Reconstitution and Preparation of PRIMAXIN Solution for Intravenous Administration

    PRIMAXIN Vials

    • Do not use diluents containing benzyl alcohol to reconstitute PRIMAXIN for administration to neonates because it has been associated with toxicity in neonates. While toxicity has not been demonstrated in pediatric patients greater than three months of age, small pediatric patients in this age range may also be at risk for benzyl alcohol toxicity.
    • Contents of the vials must be reconstituted by adding approximately 10 mL of the appropriate diluent to the vial. List of appropriate diluents are as follows:
      • 0.9% Sodium Chloride Injection
      • 5% Dextrose Injection
      • 5% Dextrose and 0.9% Sodium Chloride Injection
      • 5% Dextrose Injection with 0.225% or 0.45% saline solution
    • Reconstituted Solutions of PRIMAXIN range from colorless to yellow. Variations of color within this range do not affect the potency of the product.
    • The reconstituted suspension must not be administered by direct Intravenous Infusion
    • After reconstitution, shake vial well and transfer the resulting suspension to 100 mL of an appropriate infusion solution before administering by intravenous infusion.
    • Repeat transfer of the resulting suspension with an additional 10 mL of infusion solution to ensure complete transfer of vial contents to the infusion solution. Agitate the resulting mixture until clear.
    • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
    • Discard unused portion of the infusion solution where applicable.

    2.6 Storage of Reconstituted Solutions

    Vials (After Reconstitution)

    • PRIMAXIN, as supplied in single dose vials and reconstituted with the appropriate diluents [see Dosage and Administration (2.5)], maintains satisfactory potency for 4 hours at room temperature or for 24 hours under refrigeration (5°C). Do not freeze solutions of PRIMAXIN.

    2.7 Incompatibility and Compatibility of PRIMAXIN with other Antibacterial Drugs

    • Do not mix PRIMAXIN with, or physically add to, other antibacterial drugs.
    • PRIMAXIN may be administered concomitantly with other antibacterial drugs, such as aminoglycosides.
  • 3 DOSAGE FORMS AND STRENGTHS

    For Injection PRIMAXIN is a sterile powder mixture for reconstitution in single-dose containers including vials containing:

    • 500 mg imipenem (anhydrous equivalent) and 500 mg cilastatin sodium
  • 4 CONTRAINDICATIONS

    PRIMAXIN is contraindicated in patients who have shown hypersensitivity to any component of this product.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam. Before initiating therapy with PRIMAXIN, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens. If an allergic reaction to PRIMAXIN occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment as clinically indicated.

    5.2 Seizure Potential

    Seizures and other CNS adverse experiences, such as confusional states and myoclonic activity, have been reported during treatment with PRIMAXIN, especially when recommended dosages were exceeded [see Adverse Reactions (6.1, 6.2)]. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or compromised renal function [see Use in Specific Populations (8.6)]. However, there have been reports of CNS adverse experiences in patients who had no recognized or documented underlying CNS disorder or compromised renal function.

    Anticonvulsant therapy should be continued in patients with known seizure disorders. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN re-examined to determine whether it should be decreased or the antibacterial drug discontinued.

    5.3 Increased Seizure Potential Due to Interaction with Valproic Acid

    Case reports in the literature have shown that co-administration of carbapenems, including PRIMAXIN, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of PRIMAXIN and valproic acid/divalproex sodium is generally not recommended. Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. If administration of PRIMAXIN is necessary, supplemental anti-convulsant therapy should be considered [see Drug Interactions (7.3)]. Close adherence to the recommended dosage and dosage schedules is urged, especially in patients with known factors that predispose to convulsive activity.

    5.4 Clostridium difficile-Associated Diarrhea (CDAD)

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including PRIMAXIN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD.

    Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    5.5 Development of Drug-Resistant Bacteria

    As with other antibacterial drugs, prolonged use of PRIMAXIN may result in overgrowth of nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

    Prescribing PRIMAXIN in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Adult Patients

    During clinical investigations 1,723 patients were treated with PRIMAXIN. Table 4 shows the incidence of adverse reactions reported during the clinical investigations of adult patients treated with PRIMAXIN.

    Table 4: Incidence (%)* of Adverse Reactions Reported During Clinical Investigations of Adult Patients Treated with PRIMAXIN
    Body SystemAdverse ReactionsFrequency (%)
  • * Adverse reactions with an incidence ≥ 0.2% of PRIMAXIN-treated adult patients.
    • Local Administration sitePhlebitis/thrombophlebitis3.1%
    Pain at the injection site0.7%
    Erythema at the injection site0.4%
    Vein induration0.2%
    GastrointestinalNausea2.0%
    Diarrhea1.8%
    Vomiting1.5%
    SkinRash0.9%
    Pruritus0.3%
    Urticaria0.2%
    VascularHypotension0.4%
    Body as a WholeFever0.5%
    Nervous systemSeizures0.4%
    Dizziness0.3%
    Somnolence0.2%

    Additional adverse reactions reported in less than 0.2% of the patients or reported since the drug was marketed are listed within each body system in order of decreasing severity [see Table 5].

    Table 5: Additional Adverse Reactions Occurring in Less than 0.2% of Adult Patients Listed within Each Body System in Order of Decreasing Severity
    Body SystemAdverse Reactions
    GastrointestinalPseudomembranous Colitis (the onset of Pseudomembranous colitis symptoms), Hemorrhagic Colitis
     
    Gastroenteritis
    Abdominal Pain
    Glossitis
    Tongue Papillar
    Hypertrophy
    Heartburn
    Pharyngeal Pain
    Increased Salivation
    CNSEncephalopathy
    Confusion
    Myoclonus
    Paresthesia
    Vertigo
    Headache
    Special SensesHearing Loss
    Tinnitus
    RespiratoryChest Discomfort
    Dyspnea
    Hyperventilation
    Thoracic Spine Pain
    CardiovascularPalpitations
    Tachycardia
    SkinErythema Multiforme
    Angioneurotic Edema
    Flushing
    Cyanosis
    Hyperhidrosis
    Skin Texture Changes
    Candidiasis
    Pruritus Vulvae
    Local Administration siteInfused vein infection
    Body as a WholePolyarthralgia
    Asthenia/Weakness
    RenalOliguria/Anuria
    Polyuria

    Adverse Laboratory Changes

    The following adverse laboratory changes were reported during clinical trials:

    Hepatic: Increased alanine aminotransferase (ALT or SGPT), aspartate aminotransferase (AST or SGOT), alkaline phosphatase, bilirubin, and lactate dehydrogenase (LDH)

    Hemic: Increased eosinophils, positive Coombs test, increased WBC, increased platelets, decreased hemoglobin and hematocrit, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils

    Electrolytes: Decreased serum sodium, increased potassium, increased chloride

    Renal: Increased BUN, creatinine

    Urinalysis: Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine urobilinogen.

    Pediatric Patients

    Table 6: Incidence (%)* of Adverse Reactions Reported During Clinical Investigations of Pediatric Patients Greater Than or Equal to 3 Months of Age Treated with PRIMAXIN
    Body SystemAdverse ReactionsFrequency (%)
  • * Adverse reactions that occurred in >1 % of PRIMAXIN-treated pediatric patients (greater than or equal to 3 months of age)
    		•
    Local Administration SitePhlebitis2.2%
    Intravenous Site Irritation1.1%
    GastrointestinalDiarrhea3.9%
    Gastroenteritis1.1%
    Vomiting1.1%
    SkinRash2.2%
    RenalUrine Discoloration1.1%
    Table 7: Incidence (%)* of Adverse Reactions Reported During Clinical Investigations of Pediatric Patients Neonates to 3 Months of Age Treated with PRIMAXIN
    Body SystemAdverse ReactionsFrequency (%)
  • * Adverse reactions that occurred in >1 % of PRIMAXIN-treated pediatric patients (neonates to 3 months of age)
    		•
    GastrointestinalDiarrhea3%
    CNSConvulsions5.9%
    CardiovascularTachycardia1.5%
    SkinRash1.5%
    Body as a WholeOral Candidiasis1.5%
    RenalOliguria/Anuria2.2%

    Adverse Laboratory Changes

    The following adverse laboratory changes were reported in studies of 178 pediatric patients 3 months of age: increased AST (SGOT), decreased hemoglobin/hematocrit, increased platelets, increased eosinophils, increased ALT (SGPT), increased urine protein, decreased neutrophils.

    The following adverse laboratory changes were reported in studies of 135 patients (neonates to 3 months of age): increased eosinophils, increased AST (SGPT), increased serum creatinine, increased/decreased platelet count, increased/decreased bilirubin, increased ALT (SGPT), increased alkaline phosphatase, increased/decreased hematocrit.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of PRIMAXIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Table 8: Adverse Reactions Identified During Post Approval Use of PRIMAXIN
    Body SystemAdverse Reactions
    GastrointestinalHepatitis (including fulminant hepatitis)
    Hepatic failure
    Jaundice
    Staining of the teeth and/or tongue
    HematologicPancytopenia
    Bone marrow depression
    Thrombocytopenia
    Neutropenia
    Leukopenia
    Hemolytic anemia
    CNSTremor
    Psychic disturbances including hallucinations
    Dyskinesia
    Agitation
    Special SensesTaste perversion
    SkinStevens-Johnson syndrome
    Toxic epidermal necrolysis
    Body as a whole Drug fever
    RenalAcute renal failure
    Urine discoloration

    Adverse Laboratory Changes

    Adverse laboratory changes reported since the drug was marketed were:

    Hematologic: agranulocytosis.

    Examination of published literature and spontaneous adverse reactions reports suggested a similar spectrum of adverse reactions in adult and pediatric patients.

  • 7 DRUG INTERACTIONS

    7.1 Ganciclovir

    Generalized seizures have been reported in patients who received ganciclovir and PRIMAXIN. These drugs should not be used concomitantly with PRIMAXIN unless the potential benefits outweigh the risks.

    7.2 Probenecid

    Concomitant administration of PRIMAXIN and probenecid results in increases in the plasma level and half-life of imipenem. Therefore, it is not recommended that probenecid be given concomitantly with PRIMAXIN.

    7.3 Valproic Acid

    Case reports in the literature have shown that co-administration of carbapenems, including PRIMAXIN, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid [see Warnings and Precautions (5.3)]. The concomitant use of PRIMAXIN and valproic acid/divalproex sodium is generally not recommended. Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Available data from a small number of postmarketing cases with PRIMAXIN use in pregnancy are not sufficient to identify any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.

    Developmental toxicity studies with imipenem and cilastatin sodium (alone or in combination) administered to mice, rats, rabbits, and monkeys at doses 0.4 to 2.9 times the recommended human dose (RHD), (based on body surface area), showed no drug-induced fetal malformations.

    Embryofetal development studies with imipenem/cilastatin administered to cynomolgus monkeys at doses similar to the RHD (based on body surface area) showed an increase in embryonic loss (see Data).

    The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies within the general population.

    Data

    Animal Data

    Reproductive toxicity studies with imipenem and cilastatin (alone or in combination) administered to mice, rats, and rabbits showed no evidence of effects on embryofetal (mice, rats and rabbits) or pre/postnatal (rats) development.

    Imipenem was administered intravenously to rats (gestation days (GD) 7 to 17) and rabbits (GD 6 to 18) at doses up to 900 and 60 mg/kg/day, respectively, approximately 2.9 and 0.4 times the RHD (based on body surface area).

    Cilastatin was administered subcutaneously to rats (GD 6 to 17) and intravenously to rabbits (GD 6 to 18) at doses up to 1000 and 300 mg/kg/day, respectively, approximately 3.2 and 1.9 times the RHD (based on body surface area).

    Imipenem/cilastatin was administered intravenously to mice at doses up to 320 mg/kg/day (GD 6 to 15). In two separate studies, imipenem/cilastatin was administered to rats (GD 6 to 17 and GD 15 to day 21 postpartum) both intravenously at doses up to 80 mg/kg/day and subcutaneously at 320 mg/kg/day. The higher dose is approximately equal to the RHD (based on body surface area).

    Imipenem/cilastatin administered intravenously to pregnant cynomolgus monkeys during organogenesis at 100 mg/kg/day, approximately 0.6 times the RHD (based on body surface area), at an infusion rate mimicking human clinical use, was not associated with fetal malformations, but there was an increase in embryonic loss relative to controls. Imipenem/cilastatin administered to pregnant cynomolgus monkeys during organogenesis at 40 mg/kg/day by bolus intravenous injection caused significant maternal toxicity including death and embryofetal loss.

    8.2 Lactation

    Risk Summary

    There are insufficient data on the presence of imipenem/cilastatin in human milk, and no data on the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PRIMAXIN and any potential adverse effects on the breastfed child from PRIMAXIN or from the underlying maternal condition.

    8.4 Pediatric Use

    Use of PRIMAXIN in pediatric patients is supported by evidence from adequate and well-controlled trials of PRIMAXIN in adults and clinical studies in pediatric patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].

    PRIMAXIN is not recommended in pediatric patients with CNS infections because of the risk of seizures.

    PRIMAXIN is not recommended in pediatric patients less than 30 kg with renal impairment, as no data are available.

    8.5 Geriatric Use

    Of the approximately 3600 subjects ≥18 years of age in clinical studies of PRIMAXIN, including postmarketing studies, approximately 2800 received PRIMAXIN. Of the subjects who received PRIMAXIN, data are available on approximately 800 subjects who were 65 and over, including approximately 300 subjects who were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

    No dosage adjustment is required based on age [see Clinical Pharmacology (12.3)]. Dosage adjustment in the case of renal impairment is necessary [see Dosage and Administration (2.3)].

    8.6 Renal Impairment

    Dosage adjustment is necessary in patients with renal impairment [see Dosage and Administration (2.3)]. Adult patients with creatinine clearances of less than or equal to 30 mL/min, whether or not undergoing hemodialysis, had a higher risk of seizure activity than those without impairment of renal function [see Warnings and Precautions (5.2)]. Therefore, close adherence to the dosing guidelines and regular monitoring of creatinine clearance for these patients is recommended.

  • 10 OVERDOSAGE

    In the case of overdosage, discontinue PRIMAXIN, treat symptomatically, and institute supportive measures as required. PRIMAXIN is hemodialyzable.

  • 11 DESCRIPTION

    PRIMAXIN (imipenem and cilastatin) for Injection is a sterile formulation of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor with sodium bicarbonate added as a buffer. PRIMAXIN is an antibacterial drug for intravenous administration.

    Imipenem (N-formimidoylthienamycin monohydrate) is a crystalline derivative of thienamycin, which is produced by Streptomyces cattleya. Its chemical name is (5R,6S)-3-[[2-(formimidoylamino)ethyl]thio]-6-[(R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate. It is an off-white, nonhygroscopic crystalline compound with a molecular weight of 317.37. It is sparingly soluble in water and slightly soluble in methanol. Its empirical formula is C12H17N3O4S∙H2O, and its structural formula is:

    Chemical Structure

    Cilastatin sodium is the sodium salt of a derivatized heptenoic acid. Its chemical name is sodium (Z)-7[[(R)-2-amino-2-carboxyethyl]thio]-2-[(S)-2,2-dimethylcyclopropanecarboxamido]-2-heptenoate. It is an off-white to yellowish-white, hygroscopic, amorphous compound with a molecular weight of 380.43. It is very soluble in water and in methanol. Its empirical formula is C16H25N2O5SNa, and its structural formula is:

    Chemical Structure

    PRIMAXIN is buffered to provide solutions in the pH range of 6.5 to 8.5. There is no significant change in pH when solutions are prepared and used as directed [see How Supplied/Storage and Handling (16.1)]. PRIMAXIN 500 contains 37.5 mg of sodium (1.6 mEq). Solutions of PRIMAXIN range from colorless to yellow. Variations of color within this range do not affect the potency of the product.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    PRIMAXIN is a combination of imipenem and cilastatin. Imipenem is a penem antibacterial drug [see Microbiology (12.4)]. Cilastatin sodium is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.

    12.3 Pharmacokinetics

    Intravenous infusion of PRIMAXIN over 20 minutes results in peak plasma levels of imipenem antimicrobial activity that range from 21 to 58 mcg/mL for the 500 mg dose, and from 41 to 83 mcg/mL for the 1000 mg dose. At these doses, plasma levels of imipenem antimicrobial activity decline to below 1 mcg/mL or less in 4 to 6 hours. Peak plasma levels of cilastatin following a 20-minute intravenous infusion of PRIMAXIN range from 31 to 49 mcg/mL for the 500 mg dose, and from 56 to 88 mcg/mL for the 1000 mg dose.

    Distribution

    The binding of imipenem to human serum proteins is approximately 20% and that of cilastatin is approximately 40%.

    Imipenem has been shown to penetrate into human tissues, including vitreous humor, aqueous humor, lung, peritoneal fluid, CSF, bone, interstitial fluid, skin, and fascia. As there are no adequate and well-controlled studies of imipenem treatment in these additional body sites, the clinical significance of these tissue concentration data is unknown.

    After a 1 gram dose of PRIMAXIN, the following average levels of imipenem were measured (usually at 1 hour post dose except where indicated) in the tissues and fluids listed in Table 9:

    Table 9: Average Levels of Imipenem
    Tissue or FluidNImipenem Level mcg/mL or mcg/gRange
    Vitreous Humor33.4 (3.5 hours post dose)2.88–3.6
    Aqueous Humor52.99 (2 hours post dose)2.4–3.9
    Lung Tissue85.6 (median)3.5–15.5
    Sputum12.1—
    Pleural122.0—
    Peritoneal1223.9 S.D.±5.3 (2 hours post dose)—
    Bile25.3 (2.25 hours post dose)4.6–6.0
    CSF (uninflamed)51.0 (4 hours post dose)0.26–2.0
    CSF (inflamed)72.6 (2 hours post dose)0.5–5.5
    Fallopian Tubes113.6—
    Endometrium111.1—
    Myometrium15.0—
    Bone102.60.4–5.4
    Interstitial Fluid1216.410.0–22.6
    Skin124.4NA
    Fascia124.4NA

    Metabolism

    Imipenem, when administered alone, is metabolized in the kidneys by dehydropeptidase I, resulting in relatively low levels in urine. Cilastatin sodium, an inhibitor of this enzyme, effectively prevents renal metabolism of imipenem so that when imipenem and cilastatin sodium are given concomitantly, adequate antibacterial levels of imipenem are achieved in the urine.

    Elimination

    The plasma half-life of each component is approximately 1 hour. Approximately 70% of the administered imipenem is recovered in the urine within 10 hours after which no further urinary excretion is detectable. Urine concentrations of imipenem in excess of 10 mcg/mL can be maintained for up to 8 hours with PRIMAXIN at the 500-mg dose. Approximately 70% of the cilastatin sodium dose is recovered in the urine within 10 hours of administration of PRIMAXIN. Imipenem/cilastatin sodium is hemodialyzable [see Overdosage (10)].

    No accumulation of imipenem/cilastatin in plasma or urine is observed with regimens administered as frequently as every 6 hours in patients with normal renal function.

    Specific Populations

    Geriatric Patients

    In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of imipenem 500 mg and cilastatin 500 mg administered intravenously over 20 minutes are consistent with those expected in subjects with slight renal impairment for which no dosage alteration is considered necessary. The mean plasma half-lives of imipenem and cilastatin are 91 ± 7 minutes and 69 ± 15 minutes, respectively. Multiple dosing has no effect on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of imipenem/cilastatin is observed.

    Pediatric Patients

    Doses of 25 mg/kg/dose in patients 3 months to <3 years of age, and 15 mg/kg/dose in patients 3-12 years of age were associated with mean trough plasma concentrations of imipenem of 1.1±0.4 mcg/mL and 0.6±0.2 mcg/mL following multiple 60-minute infusions, respectively; trough urinary concentrations of imipenem were in excess of 10 mcg/mL for both doses. These doses have provided adequate plasma and urine concentrations for the treatment of non-CNS infections.

    In a dose-ranging study of smaller premature infants (670-1,890 g) in the first week of life, a dose of 20 mg/kg q12h by 15-30 minutes infusion was associated with mean peak and trough plasma imipenem concentrations of 43 mcg/mL and 1.7 mcg/mL after multiple doses, respectively. However, moderate accumulation of cilastatin in neonates may occur following multiple doses of PRIMAXIN. The safety of this accumulation is unknown.

    12.4 Microbiology

    Mechanism of Action

    PRIMAXIN is a combination of imipenem and cilastatin. The bactericidal activity of imipenem results from the inhibition of cell wall synthesis. Its greatest affinity is for penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of Escherichia coli, and 1A, 1B, 2, 4 and 5 of Pseudomonas aeruginosa. The lethal effect is related to binding to PBP 2 and PBP 1B.

    Imipenem has a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases produced by Gram-negative and Gram-positive bacteria. It is a potent inhibitor of beta-lactamases from certain Gram-negative bacteria which are inherently resistant to most beta-lactam antibacterials, e.g., Pseudomonas aeruginosa, Serratia spp., and Enterobacter spp.

    Resistance

    Imipenem is inactive in vitro against Enterococcus faecium, Stenotrophomonas maltophilia and some isolates of Burkholderia cepacia. Methicillin-resistant staphylococci should be reported as resistant to imipenem.

    Interaction with Other Antimicrobials

    In vitro tests show imipenem to act synergistically with aminoglycoside antibacterials against some isolates of Pseudomonas aeruginosa.

    Antimicrobial Activity

    Imipenem has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)].

    Aerobic bacteria

    •   Gram-positive bacteria
    •   Enterococcus faecalis
    •   Staphylococcus aureus
    •   Staphylococcus epidermidis
    •   Streptococcus agalactiae (Group B streptococci)
    •   Streptococcus pneumoniae
    •   Streptococcus pyogenes
    •   Gram-negative bacteria
    •   Acinetobacter spp.
    •   Citrobacter spp.
    •   Enterobacter spp.
    •   Escherichia coli
    •   Gardnerella vaginalis
    •   Haemophilus influenzae
    •   Haemophilus parainfluenzae
    •   Klebsiella spp.
    •   Morganella morganii
    •   Proteus vulgaris
    •   Providencia rettgeri
    •   Pseudomonas aeruginosa
    •   Serratia spp., including S. marcescens

    Anaerobic bacteria

    •   Gram-positive bacteria
    •   Bifidobacterium spp.
    •   Clostridium spp.
    •   Eubacterium spp.
    •   Peptococcus spp.
    •   Peptostreptococcus spp.
    •   Propionibacterium spp.
    •   Gram-negative bacteria
    •   Bacteroides spp., including B. fragilis
    •   Fusobacterium spp.

    The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for imipenem against isolates of similar genus or organism group. However, the efficacy of imipenem in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials.

    Aerobic bacteria

    •   Gram-positive bacteria
    •   Bacillus spp.
    •   Listeria monocytogenes
    •   Nocardia spp.
    •   Staphylococcus saprophyticus
    •   Group C streptococci
    •   Group G streptococci
    •   Viridans group streptococci
    •   Gram-negative bacteria
    •   Aeromonas hydrophila
    •   Alcaligenes spp.
    •   Capnocytophaga spp.
    •   Haemophilus ducreyi
    •   Neisseria gonorrhoeae
    •   Pasteurella spp.
    •   Providencia stuartii

    Anaerobic bacteria

    •   Prevotella bivia
    •   Prevotella disiens
    •   Prevotella melaninogenica
    •   Veillonella spp.

    Susceptibility Testing

    For specific information regarding susceptibility test methods, interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long term studies in animals have not been performed to evaluate carcinogenic potential of imipenem/cilastatin. A variety of bacterial and mammalian tests were performed to evaluate genetic toxicity. The tests used were: V79 mammalian cell mutagenesis assay (cilastatin sodium alone and imipenem alone), Ames test (cilastatin sodium alone and imipenem alone), unscheduled DNA synthesis assay (imipenem/cilastatin sodium) and in vivo mouse cytogenetics test (imipenem/cilastatin sodium). None of these tests showed any evidence of genetic alterations.

    Impairment of fertility or reproductive performance was not observed in male and female rats given imipenem/cilastatin at intravenous doses up to 80 mg/kg/day and at a subcutaneous dose of 320 mg/kg/day. In rats, a dose of 320 mg/kg/day was approximately equal to the highest recommended human dose based on body surface area.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    PRIMAXIN is supplied as a sterile powder mixture in single dose containers including vials containing imipenem (anhydrous equivalent) and cilastatin sodium as follows:

    Each PRIMAXIN Package Contains:National Drug Code (NDC) Number
    A tray of 25 vials containing 500 mg imipenem equivalent and 500 mg cilastatin equivalent and 20 mg sodium bicarbonate as a buffer.(NDC: 0006-3516-59)

    16.2 Storage and Handling

    Before Reconstitution:

    The dry powder should be stored at a temperature below 25°C (77°F).

  • 17 PATIENT COUNSELING INFORMATION

    • Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. They should report any previous hypersensitivity reactions to PRIMAXIN, other carbapenems, beta-lactams or other allergens.
    • Counsel patients that antibacterial drugs including PRIMAXIN should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When PRIMAXIN is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by PRIMAXIN or other antibacterial drugs in the future.
    • Counsel patients to inform their physician:
      • if they have central nervous system disorders such as stroke or history of seizures. Seizures have been reported during treatment with PRIMAXIN and with closely related antibacterial drugs.
      • if they are taking valproic acid or sodium valproate. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-administration with PRIMAXIN. If treatment with PRIMAXIN is necessary and continued, alternative or supplemental anti-convulsant medication to prevent and/or treat seizures may be needed.
    • Advise patients that diarrhea is a common problem caused by antibacterial drugs and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, patients should contact their healthcare provider.
  • SPL UNCLASSIFIED SECTION

    Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

    Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    All rights reserved.

    uspi-mk0787b-iv-1909r043

  • PRINCIPAL DISPLAY PANEL 250 mg Bottle Label

    NDC: 0006-3514-58

    250
    PRIMAXIN® I.V.
    (IMIPENEM AND CILASTATIN FOR INJECTION)

    IMIPENEM 250 mg (Anhydrous Equivalent)
    CILASTATIN EQUIVALENT 250 mg
    CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
    NOT FOR DIRECT INFUSION

    Rx only
    250 mg

    Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

    3514

    PRINCIPAL DISPLAY PANEL 250 mg Bottle Label
  • PRINCIPAL DISPLAY PANEL - 500 mg Vial Package

    1 PACKAGE (25 VIALS)
    NDC: 0006-3516-59

    500
    PRIMAXIN® I.V.
    (IMIPENEM AND CILASTATIN FOR INJECTION)

    Not to be divided.

    IMIPENEM 500 mg (Anhydrous Equivalent) CILASTATIN EQUIVALENT 500 mg
    Inactive ingredient: sodium bicarbonate 20 mg added to each vial as a buffer.
    CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY / NOT FOR DIRECT INFUSION
    For the Preparation of Intravenous Solutions and USUAL ADULT DOSAGE: See
    accompanying circular. Color changes in solution from colorless to
    yellow do not affect potency. Store dry material below 25ºC.

    Rx only

    Merck Sharp & Dohme Corp.,
    a subsidiary of
    MERCK & CO., INC.
    Whitehouse Station, NJ 08889, USA

    PRINCIPAL DISPLAY PANEL - 500 mg Vial Package
  • PRINCIPAL DISPLAY PANEL - Single-Dose ADD-Vantage Vial 250 mg

    NDC: 0006-3551-58

    Single-dose ADD-Vantage® vial

    250

    PRIMAXIN® I.V.

    (IMIPENEM AND CILASTATIN FOR INJECTION)

    IMIPENEM 250 mg (Anhydrous Equivalent)
    CILASTATIN EQUIVALENT 250 mg

    CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
    NOT FOR DIRECT INFUSION

    PRIMAXIN is a registered trademark of Merck Sharp & Dohme Corp.

    ADD-Vantage is a registered trademark of ABBOTT LABORATORIES, Inc.

    9960800

    For the Preparation of Intravenous Solutions and USUAL ADULT DOSAGE: See accompanying circular.

    Store dry material below 25°C.

    After constitution as directed, the solution maintains satisfactory potency for 4 hours at room temperature.

    Consult accompanying INSTRUCTIONS FOR USE.

    Use only with ADD-Vantage® Diluent Containers.

    Rx only

    250 mg | No. 3551

    Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC.
    Whitehouse Station, NJ 08889, USA

    Single-Dose ADD-Vantage Vial 250 mg
  • PRINCIPAL DISPLAY PANEL - Single-Dose ADD-Vantage Vial 500 mg

    NDC: 0006-3552-59

    Single-dose ADD-Vantage® vial

    500

    PRIMAXIN® I.V.

    (IMIPENEM AND CILASTATIN FOR INJECTION)

    IMIPENEM 500 mg (Anhydrous Equivalent)
    CILASTATIN EQUIVALENT 500 mg

    CAUTION: SINGLE DOSE VIAL / FOR I.V. USE ONLY
    NOT FOR DIRECT INFUSION

    PRIMAXIN is a registered trademark of Merck Sharp & Dohme Corp.

    ADD-Vantage is a registered trademark of ABBOTT LABORATORIES, Inc.

    9940700

    For the Preparation of Intravenous Solutions and USUAL ADULT DOSAGE: See accompanying circular.

    Store dry material below 25°C.

    After constitution as directed, the solution maintains satisfactory potency for 4 hours at room temperature.

    Consult accompanying INSTRUCTIONS FOR USE.

    Use only with ADD-Vantage® Diluent Containers.

    Rx only

    500 mg | No. 3552

    Merck Sharp & Dohme Corp., a subsidiary of
    MERCK & CO., INC.
    Whitehouse Station, NJ 08889, USA

    Single-Dose ADD-Vantage Vial 500 mg
  • INGREDIENTS AND APPEARANCE
    PRIMAXIN  IV
    imipenem and cilastatin sodium injection, powder, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0006-3514
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    IMIPENEM (UNII: 71OTZ9ZE0A) (IMIPENEM ANHYDROUS - UNII:Q20IM7HE75) IMIPENEM ANHYDROUS250 mg  in 100 mL
    CILASTATIN SODIUM (UNII: 5428WXZ74M) (CILASTATIN - UNII:141A6AMN38) CILASTATIN250 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM BICARBONATE (UNII: 8MDF5V39QO) 10 mg  in 100 mL
    Product Characteristics
    ColorYELLOW (colorless to yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0006-3514-5825 in 1 TRAY11/26/198505/01/2017
    1100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA05058711/26/198505/01/2017
    PRIMAXIN  IV
    imipenem and cilastatin sodium injection, powder, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0006-3516
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    IMIPENEM (UNII: 71OTZ9ZE0A) (IMIPENEM ANHYDROUS - UNII:Q20IM7HE75) IMIPENEM ANHYDROUS500 mg  in 100 mL
    CILASTATIN SODIUM (UNII: 5428WXZ74M) (CILASTATIN - UNII:141A6AMN38) CILASTATIN500 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM BICARBONATE (UNII: 8MDF5V39QO) 20 mg  in 100 mL
    Product Characteristics
    ColorYELLOW (colorless to yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0006-3516-5925 in 1 TRAY11/26/1985
    1100 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA05058711/26/1985
    PRIMAXIN  IV
    imipenem and cilastatin sodium injection, powder, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0006-3551
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    IMIPENEM (UNII: 71OTZ9ZE0A) (IMIPENEM ANHYDROUS - UNII:Q20IM7HE75) IMIPENEM ANHYDROUS250 mg  in 100 mL
    CILASTATIN SODIUM (UNII: 5428WXZ74M) (CILASTATIN - UNII:141A6AMN38) CILASTATIN250 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM BICARBONATE (UNII: 8MDF5V39QO) 10 mg  in 100 mL
    Product Characteristics
    ColorYELLOW (colorless to yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0006-3551-5825 in 1 TRAY01/08/198705/31/2016
    1100 mL in 1 VIAL, PHARMACY BULK PACKAGE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06275601/08/198705/31/2016
    PRIMAXIN  IV
    imipenem and cilastatin sodium injection, powder, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0006-3552
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    IMIPENEM (UNII: 71OTZ9ZE0A) (IMIPENEM ANHYDROUS - UNII:Q20IM7HE75) IMIPENEM ANHYDROUS500 mg  in 100 mL
    CILASTATIN SODIUM (UNII: 5428WXZ74M) (CILASTATIN - UNII:141A6AMN38) CILASTATIN500 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM BICARBONATE (UNII: 8MDF5V39QO) 20 mg  in 100 mL
    Product Characteristics
    ColorYELLOW (colorless to yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0006-3552-5925 in 1 TRAY01/08/198705/31/2016
    1100 mL in 1 VIAL, PHARMACY BULK PACKAGE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06275601/08/198705/31/2016
    Labeler - Merck Sharp & Dohme Corp. (001317601)

    • Trademark Results [PRIMAXIN]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    PRIMAXIN
    PRIMAXIN
    73446124 1297360 Live/Registered
    Merck & Co., Inc.
    1983-09-30
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.